ARTICLE | Company News
Sequitur, Vertex deal
October 9, 2000 7:00 AM UTC
VRTX gained access to Sequitur’s antisense functional genomics compounds and technology for use in target validation studies. VRTX will pay licensing fees and provide research funding to Sequitur. ...